Fadogia Agrestis: Testosterone Support, Dosage, and Safety Concerns

At a Glance

Fadogia agrestis has gone from obscure West African botanical to one of the most-discussed testosterone supplements on the internet in roughly three years — driven largely by podcast endorsements and social media. My inbox reflects this: men in their 30s and 40s asking whether to add it to their stack, often already taking it.

The honest clinical answer is: we do not yet know enough to recommend it confidently, and what we do know about high-dose toxicity should make anyone cautious. That does not mean it is inert — the rodent pharmacology is real and interesting — but the gap between “works in rats” and “safe and effective in men” is exactly the gap that human trials exist to close.

What Is Fadogia Agrestis?

Fadogia agrestis is a small shrub in the Rubiaceae family native to the savanna regions of Nigeria, Sudan, and Cameroon. Traditional healers in these areas have long used the stem bark as an aphrodisiac and remedy for erectile dysfunction — a pattern that drew the attention of Nigerian pharmacologists in the early 2000s.

The plant contains saponins, alkaloids (including anthraquinones), and flavonoids. The saponin fraction is most consistently associated with androgenic effects in animal models, though the exact active compound has not been isolated and standardized in commercial extracts.

Proposed Mechanism: LH Stimulation

The dominant hypothesis is that Fadogia agrestis increases serum luteinizing hormone (LH), which then drives Leydig cell synthesis of testosterone in the testes. This is distinct from exogenous testosterone (which suppresses LH via negative feedback) and more similar in concept to how Tongkat Ali (eurycoma longifolia) is thought to work.

In the foundational 2005 study by Yakubu and colleagues, male rats given aqueous stem extract showed dose-dependent increases in serum testosterone at 18, 36, and 72 mg/kg/day over five weeks. Alkaline phosphatase — a marker of testicular enzyme activity — also increased, consistent with enhanced Leydig cell function.

Two subsequent studies from the same group demonstrated effects on sexual behavior parameters (mounting frequency, intromission latency) in rats, which correlates with androgenic activity.

What This Does NOT Tell Us

These are rodent studies using aqueous (water-based) extracts. The pharmacokinetics in humans differ. Allometric dose scaling from rats to humans is imprecise, particularly for botanical compounds. Most importantly, no study has measured serum LH and testosterone in human subjects before and after standardized Fadogia supplementation under controlled conditions.

The Safety Problem: Gonadotoxicity

This is where the story gets complicated. The same research group that documented testosterone-boosting effects also found dose-dependent testicular toxicity in rats:

• At 1,000 mg/kg/day (five weeks), rats showed reduced testicular weight, degeneration of seminiferous tubule epithelium, and reduced sperm count.
• Histopathological analysis revealed interstitial edema and Sertoli cell disruption — the very cells that support spermatogenesis.
• Liver enzyme elevations (ALT, AST) were also observed at high doses, suggesting hepatotoxicity is a secondary concern.

The 2008 Yakubu and Akanji study is the key reference here. The authors explicitly cautioned against prolonged high-dose use in the abstract, a note that tends to get lost when the research is cited on supplement forums.

Allometric Scaling and Human Dose Equivalents

The gonadotoxic dose in rats (1,000 mg/kg) does not directly translate to human exposure. Standard allometric scaling (using the body surface area formula Km = 6 for rats, Km = 37 for humans) yields a rough human equivalent dose of approximately 163 mg/kg — which for a 75 kg man would be roughly 12,000 mg/day. Most commercial products provide 425–600 mg/day.

This margin offers some reassurance that marketed doses are probably far below the gonadotoxic threshold — but the absence of human pharmacokinetic data means we cannot confirm this. Bioavailability, extract standardization, and cumulative long-term effects remain completely unstudied in humans.

What Human Evidence Exists?

As of mid-2026, I am not aware of any published, peer-reviewed, randomized controlled trials examining Fadogia agrestis supplementation in humans for testosterone, LH, sperm parameters, or safety endpoints. Anecdotal reports circulate widely online, but these are subject to the usual confounders: concurrent supplement use, training status changes, regression to the mean, and reporting bias.

This absence of human data is not unusual for botanicals — it reflects the economics of researching non-patentable compounds — but it is clinically relevant when making a recommendation. For comparison, Tongkat Ali has at least seven published human RCTs including a multi-center trial in men with late-onset hypogonadism showing meaningful free testosterone increases. Ashwagandha KSM-66 has similarly robust human data for stress hormone reduction and modest testosterone effects.

Who Is Taking It and Why

In my practice and in the functional medicine community, I see Fadogia agrestis most often in:

• Men aged 30–50 with suboptimal total testosterone (350–500 ng/dL) who want to optimize without starting testosterone replacement therapy (TRT)
• Men on TRT who are concerned about testicular atrophy and want to support endogenous LH/testosterone production
• Recreational athletes and bodybuilders stacking it with other “natural testosterone support” compounds (typically combined with Tongkat Ali, zinc, and ashwagandha)

The third group often uses it in cycling protocols (8–12 weeks on, 4 weeks off), borrowing a framework from anabolic steroid protocols without clear justification for Fadogia specifically.

Practical Guidance for Patients Asking About It

Given current evidence, here is how I approach this conversation:

If testosterone is genuinely suboptimal: Prioritize comprehensive hormone testing, addressing sleep, body composition, and cortisol burden first. Consider Tongkat Ali LJ100 (200–400 mg/day) or KSM-66 ashwagandha (600 mg/day) as first-line botanicals — both have human safety and efficacy data.

If already taking Fadogia: I am not alarmed at typical marketed doses (425–600 mg/day) short-term, but I ask patients to monitor: testicular discomfort (a potential early warning sign), libido changes, and to obtain testosterone, LH, FSH, and LFTs at baseline and 8 weeks. I advise against doses above 1,000 mg/day and against continuous use beyond 12 weeks without a documented benefit and re-evaluation.

If stacking with TRT: The logic of combining an LH stimulator with exogenous testosterone is questionable — exogenous testosterone suppresses LH and testicular Leydig cell activity regardless of botanical support. If testicular atrophy on TRT is the concern, human chorionic gonadotropin (hCG) or gonadorelin are the pharmacologically rational choices, not botanical LH stimulators.

Contraindications to keep in mind:

• Pre-existing hepatic disease (pending liver safety data)
• Active testicular pathology or oligospermia (until reproductive safety data exist)
• Patients planning fertility in the near term (unknown sperm impact in humans)
• Concurrent use of hepatotoxic medications (additive risk)

Comparison with Better-Studied Alternatives

This comparison is not intended to dismiss Fadogia entirely — it may yet prove effective and safe in human trials — but to contextualize it against the evidence hierarchy.

Related Articles

• Tongkat Ali: Clinical Evidence and Dosage
• Testosterone Optimization for Men
• Hormone Testing: What to Measure and When
• Hormone Optimization for Longevity
• Ashwagandha: Cortisol, Stress, and Testosterone

References

1. Yakubu MT, Akanji MA, Oladiji AT. Aphrodisiac potentials of the aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male albino rats. Asian J Androl. 2005;7(4):399-404. PMID: 16110353

2. Yakubu MT, Akanji MA, Oladiji AT. Male sexual dysfunction and methods used in assessing medicinal plants with aphrodisiac potentials. Pharmacognosy Rev. 2007;1(1):49-56.

3. Yakubu MT, Akanji MA. Effect of aqueous extract of Fadogia agrestis stem on sexual behaviour and hormonal status of male Wistar rats. Andrologia. 2011;43(3):167-174. PMID: 21486397

4. Yakubu MT, Akanji MA. Toxicological evaluation of aqueous root extract of Fadogia agrestis in male rats. Andrologia. 2008;40(5):288-294. PMID: 18811872

5. Tambi MI, Imran MK, Henkel RR. Standardised water-soluble extract of Eurycoma longifolia, Tongkat Ali, as testosterone booster for managing men with late-onset hypogonadism. Andrologia. 2012;44 Suppl 1:226-230. PMID: 21671978

6. Lopresti AL, Drummond PD, Smith SJ. A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (Withania somnifera) in aging, overweight males. Am J Mens Health. 2019;13(2):1557988319835985. PMID: 30854916

7. Pilz S, Frisch S, Koertke H, et al. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res. 2011;43(3):223-225. PMID: 21154195